Pfizer Inks Diabetes Discovery Collaboration With Sanford-Burnham
This article was originally published in The Pink Sheet Daily
Executive Summary
The New York-based pharma continues to delve further into the diabetes research space despite not currently having a commercial presence in the therapeutic area. Pfizer’s latest tie-up will help it identify targets that could be used in the treatment of diabetes and obesity.
You may also be interested in...
Tech Transfer Roundup: Academia's Role In De-Risking Novel Science
The Sanford Burnham Prebys institute is driving innovation in areas like neurodegenerative disease and immuno-oncology. Plus the latest tech transfer deals: two in cancer, one in asthma/allergies and another in lipid nanoparticle technology.
Merck And Pfizer Make A Late Play For The Diabetes Market
Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.